Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28937232 | 0.84 | TSHR (0.45) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL1760529 | 0.82 | CA1 (0.70) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL3435343 | 0.80 | CA1 (0.46) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL4714238 | 0.78 | GABRA1 (0.52) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL21251576 | 0.78 | CA1 (0.44) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL6282235 | 0.78 | CA1 (0.44) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL4715891 | 0.78 | CA1 (0.44) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL4713540 | 0.78 | GABRA1 (0.52) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL4712954 | 0.78 | GABRA1 (0.52) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL10951011 | 0.78 | CA1 (0.44) | GABRA1GABRB1CA1CA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179302-A1 | USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | XI'AN LIBANG PHARMACEUTICAL CO., LTD (CN) | 2020-06-11 | — | — | US | claimed |
| US-20180185299-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | XI'AN LIBANG PHARMACEUTICAL CO., LTD (CN) | 2018-07-05 | — | — | US | claimed |
| EP-3246022-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | Xi'an Libang Pharmaceutical Co., Ltd (CN) | 2017-11-22 | — | — | EP | claimed |
| EP-3845225-B1 | GABAA RECEPTOR ALLOSTERIC ENHANCER FOR USE IN THE TREATMENT OF EPILEPSY | XIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-11684591-B2 | Use of a GABAA receptor allosteric enhancer in medicine | XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD (CN) | 2023-06-27 | — | — | US | disclosed |
| US-20210315835-A1 | USE OF A GABAA RECEPTOR ALLOSTERIC ENHANCER IN MEDICINE | XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD (CN) | 2021-10-14 | — | — | US | disclosed |
| CN-113491680-A | Application of catechol and derivatives in preparation of drugs for treating sleep disorders | 西安力邦肇新生物科技有限公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-3845225-A1 | APPLICATION OF GABAA RECEPTOR ALLOSTERIC ENHANCER IN MEDICINE | Xi'an Libang Zhaoxin Biotechnology Co., Ltd. (CN) | 2021-07-07 | — | — | EP | disclosed |
| US-20200179302-A1 | USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | XI'AN LIBANG PHARMACEUTICAL CO., LTD (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200179302-A1 | USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | XI'AN LIBANG PHARMACEUTICAL CO., LTD (CN) | 2020-06-11 | — | — | US | disclosed |
| CN-110872213-A | GABAAReceptor allostericEnhancing compounds, their preparation and use | 西安力邦肇新生物科技有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-20180185299-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | XI'AN LIBANG PHARMACEUTICAL CO., LTD (CN) | 2018-07-05 | — | — | US | disclosed |
| EP-3246022-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | Xi'an Libang Pharmaceutical Co., Ltd (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246022-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | Xi'an Libang Pharmaceutical Co., Ltd (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-1917311-B1 | Rylene based multiple chromophores | BASF SE (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8501948-B2 | Multiple chromophores based on rylene | BASF AKTIENGESELLSCHAFT (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20080287678-A1 | Multiple Chromophores Based on Rylene | BASF AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | US | disclosed |
| US-4158027-A | BIPHENOL DERIVATIVES USED AS POLYMERIZATION INHIBITORS | ICI AMERICAS INC. (US) | 1979-06-12 | — | — | US | disclosed |
| US-4112019-A | BISPHENOL POLYMERIZATION INHIBITOR | ICI AMERICAS INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4049731-A | VINYL MONOMERS, BIPHENOL DERIVATIVE AS POLYMERIZATION INHIBITOR | ICI UNITED STATES INC. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179302-A1 | USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | PTGER3, PTGES3, CYP24A1 | GABRA1 1095/4885GABRB1 988/4885CA1 231/4885 |
| US-11684591-B2 | Use of a GABAA receptor allosteric enhancer in medicine | GABRE, GABRB2, GABRB1 | GABRA1 7/4885GABRB1 3/4885CA1 2867/4885 |
| US-20210315835-A1 | USE OF A GABAA RECEPTOR ALLOSTERIC ENHANCER IN MEDICINE | GABRE, GABRB2, GABRB1 | GABRA1 7/4885GABRB1 3/4885CA1 2867/4885 |
| US-20080287678-A1 | Multiple Chromophores Based on Rylene | TDO2, PPOX, NPY1R | GABRA1 2209/4885GABRB1 2271/4885CA1 1222/4885 |
| US-20180185299-A1 | THE USE OF DIPHENOL IN PREPARATION OF MEDICINES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | PTGER3, CYP24A1, PTGES3 | GABRA1 1178/4885GABRB1 1053/4885CA1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.